deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02556632

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer (Curcumin-II)

Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis

Sponsor: Gary Morrow

Conditions Breast Carcinoma Pain Radiation-Induced Dermatitis Stage 0 Breast Cancer
Interventions Curcumin-based Gel Dermatologic Complications Management Laboratory Biomarker Analysis Placebo Questionnaire Administration
Updated 8 times since 2017 Last updated: Oct 4, 2017 Started: Oct 13, 2015 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02556632, this PHASE2 trial focuses on Breast Carcinoma and Pain and remains completed. Sponsored by Gary Morrow, it has been updated 8 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshotCompleted~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshotCompleted~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Dec 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2017 — Dec 2017 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2017 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gary Morrow
  • National Cancer Institute (NCI)
Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations